transplant Flashcards
3 specific infection risks with Rituximab
Hep B reactivation
PML
PCP pneumonia
Alemtuzimab 3 specific infection risks
CMV
PCP pneumonia
aspergillus
imatinib infection risks
VZV
Mold infections
Hep B reactivation
ibrutinib infection risks
aspergillosis including CNS
risks of venetoclax
severe prolonged neutropenia
drug interaction with venetoclax
fluconazole, can increase dose of venetoclax and induce worsening of neutropenia
Neutropenic patient on FQ prophylaxis with ARDS, rash, mucositis
strep viridian’s
Neutropenic patient with sepsis on B lactam therapy
Stenotrophomonas or ESBL
Neutropenic patient with sepsis while on carbapenem
ESBL
Neutropenic patient with lung and skin lesions
Pseudomonas aeuroginosa or Fungi
neutropenic patient with skin lesions, Gram + organism
Corynebacterium jeikeium
neutropenic patient with small tender papule on skin
candida
neutropenic patients with ulcerative and necrotic lesions on skin
aspergillus
neutropenic patient with multiple erythematous lesions in different stages
fusarium
atypical presentations of fusarium
keratitis
onychomycosis
neutropenic patient with tender plaques and nodules recently received G CSF
sweet’s syndrome
resolved neutropenia, post engraftment abdominal pain, increased LFTs, fever, leg/flank pain
hepatosplenic candidiasis
inflammatory response to fungi invaded into portal vasculature
high risk CMV status in BMT
D-, R +
presentation of toxoplasmosis in BMT
pneumonia, encephalitis, fever
BOOP/COP presentation
progressively indolent hypoxia and cough
etiology of COP/BOOP
fibrosis of terminal airways leading to airflow obstructionP
PRES timing after HSCT
within first three months after HSCT
PRES medication risks
calcineurin inhibitors
